

ASX Announcement

27 January 2026

Mr Mark McConnell appointed to the Board

BCAL Diagnostics Limited (ASX: BDX) ("BCAL" or the "Company"), an Australian healthcare company engaged in early cancer detection, announces the appointment of Mark McConnell as a Non-Executive Director of BCAL with effect from 1 February 2026.

Mr McConnell led Magentus through its successful transformation into a leading global health technology company. He was co-founder of The Citadel Group Limited (formerly listed on the ASX), a software and services company, and the predecessor to what is now Magentus Group Pty Ltd.

Mr McConnell is a successful business developer whose skills cover the areas of business strategy, investor relations, capital raising and innovation. After serving as an officer in the Royal Australian Air Force for almost a decade, Mark moved into the corporate world and for the past 28 years has worked across various executive roles in aviation, technology and investment banking.

Mr McConnell has a strong commitment to community and has served on the boards of numerous charities, not for profit and sporting organisations. He is also a Non-Executive Director of Adveritas Ltd (ASX: AV1).

BCAL Executive Chair, Jayne Shaw, said: *"BCAL is very pleased to have someone of Mark's calibre join the Board. Mark brings extensive ASX experience and leadership skills to BCAL. His proven track record in scaling healthcare technology businesses, executing complex transformations and engaging effectively with investors will be highly valuable as BCAL progresses the commercialisation of BREASTEST plus™ and advances its broader growth strategy. We look forward to working with Mark as the Company enters its next phase of development"*.

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

For further information:

Corporate

Jayne Shaw

jshaw@bcaldiagnostics.com

+61 (0) 412 292 446

Corporate

Shane Ryan

sryan@bcaldiagnostics.com

+61 (0) 437 192 869

Media

Rama Razy

rama.razy@automicgroup.com.au

+61 (0) 498 440 142

About BCAL Diagnostics

BCAL Diagnostics (ASX: BDX) is an Australian healthcare company engaged in early cancer detection. BCAL is focussed on advancing early and accurate breast cancer detection via BREASTEST plus™ a non-invasive, lipid-based 'rule-out' test designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

Also, BCAL maintains an exclusive licence agreement with ClearNote Health, a US-based precision diagnostics company, for the distribution of ClearNote's pancreatic and ovarian cancer blood tests in Australia.

Founded in 2010, BCAL is headquartered in Sydney.

For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.